诚信认证：
工商注册信息已核实！
快速导航
产品分类
微信二维码
Minisite
QQ号咨询
血管生成
Bafetinib (INNO-406)
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
产品参数
| 货号 | CAS号 | 操作 |
|---|---|---|
| B129232-100mg | 859212-16-1 | 询价 |
| B129232-25mg | 859212-16-1 | 询价 |
| B129232-5mg | 859212-16-1 | 询价 |
产品介绍
- 分子式 C30H31F3N8O
- 分子量576.62
属性
| 溶解性 | DMSO 115 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
| 存贮条件 | 储存温度-20°C |
描述
| 产品介绍 | Bafetinib (INNO-406)是一种有效的，选择性的，Bcr-Abl/Lyn双重抑制剂，IC50为5.8 nM/19 nM，对T315I突变型的磷酸化没有抑制作用，对PDGFR和c-Kit的作用效果稍弱。 |
| 生化机理 | Bafetinib (1-10 μM) concentration dependently inhibits PAR2-TRPV4 coupling. In TRPV4 HEKs, 10 μM Bafetinib significantly inhibits the coupling response to SLIGRL and trypsin compared with vehicle control. Bafetinib inhibits the signalling pathway leading to TRPV4 channel opening, downstream of PAR2 activation, most likely by blocking the activation of a tyrosine kinase. Bafetinib blocks WT Bcr-Abl autophosphorylation and its downstream kinase activity with IC50 of 11 nM and 22 nM in K562 and 293T cells, respectively. Bafetinib suppresses the growth of the Bcr-Abl-positive cell lines including K562, KU812, and BaF3/wt cells potently without effects on the proliferation of the Bcr-Abl-negative U937 cell line. Moreover, Bafetinib exhibits a dose-dependent antiproliferative effect against Bcr-Abl point mutant cell lines, such as BaF3/E255K cells |
| 别名 | NS-187;巴非替尼; N-[3-([4,5'-联嘧啶]-2-基氨基)-4-甲基苯基]-4-[[(3S)-3-(二甲基氨基)-1-吡咯烷基]甲基]-3-(三氟甲基)苯甲酰胺;NS-187;N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)benzamide |
Bafetinib (INNO-406)信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于Bafetinib (INNO-406)报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途